Insilico Medicine Nominates AI-Designed ISM9077 as Preclinical Candidate for Ocular Diseases
HONG KONG, August 5, 2026 Insilico Medicine has announced the nomination of ISM9077 as its 32nd Preclinical Candidate (PCC)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HONG KONG, August 5, 2026 Insilico Medicine has announced the nomination of ISM9077 as its 32nd Preclinical Candidate (PCC)...
